Kymera Therapeutics (KYMR) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $9.52B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Nello Mainolfi |
| IPO Date | 2020-08-21 | CAGR | — |
| Employees | 253 | Website | www.kymeratx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| Enterprise Value | $11.04B | P/E Ratio | -32.8 |
| Forward P/E | -26.22 | PEG Ratio | — |
| P/S Ratio | 42981.12 | P/B Ratio | 1706.26 |
| P/CF Ratio | -10809.48 | P/FCF Ratio | -9067.83 |
| EPS | $-3.53 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -12.6% | Gross Margin | 1% |
| Operating Margin | -6.98% | Profit Margin | -6.12% |
| ROE | -0.25% | ROA | -0.19% |
| ROCE | -0.22% | Current Ratio | 10.81 |
| Quick Ratio | 10.81 | Cash Ratio | 2.3 |
| Debt/Equity | 0.05 | Interest Coverage | -1508.94 |
| Altman Z Score | 42.81 | Piotroski Score | 2 |
Kymera Therapeutics (KYMR) valuation & financials
Kymera Therapeutics (KYMR) has a market capitalization of $9.52B and trades at a price-to-earnings ratio of -32.8. It operates in the Healthcare sector (Biotechnology).
Kymera Therapeutics's revenue grew -12.6% over the last year.
Kymera Therapeutics's next earnings report is scheduled for August 10, 2026 before market open; analysts estimate EPS of $-0.73.
Kymera Therapeutics (KYMR) — frequently asked questions
When does Kymera Therapeutics (KYMR) report earnings next?
Kymera Therapeutics is expected to report earnings on August 10, 2026 before market open. Analysts estimate EPS of $-0.73.
What is Kymera Therapeutics's market cap?
Kymera Therapeutics (KYMR) has a market capitalization of $9.52B.
What is KYMR's P/E ratio?
Kymera Therapeutics trades at a price-to-earnings ratio of -32.8, with trailing twelve-month EPS of $-3.53.
How fast is Kymera Therapeutics growing?
Kymera Therapeutics's revenue grew -12.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)